Literature DB >> 21689627

An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.

Piia-Riitta Karhemo1, Antti Rivinoja, Johan Lundin, Maija Hyvönen, Anastasiya Chernenko, Johanna Lammi, Harri Sihto, Mikael Lundin, Päivi Heikkilä, Heikki Joensuu, Petri Bono, Pirjo Laakkonen.   

Abstract

Nucleophosmin (NPM) is a multifunctional protein involved in a complex network of interactions. The role of NPM in oncogenesis is controversial. The NPM gene (NPM1) is mutated or rearranged in a number of hematological disorders, but such changes have not been detected in solid cancers. However, experiments with cultured NPM-null cells and with mice carrying a single inactivated NPM allele indicate a tumor suppressor function for NPM. To resolve the role of NPM in solid cancers, we examined its expression and localization in histologically normal breast tissue and a large array of human breast carcinoma samples (n = 1160), and also evaluated its association with clinicopathological variables and patient survival. The intensity and localization (nucleolar, nuclear, cytoplasmic) of NPM varied across clinical samples. No mutations explaining the differences were found, but the present findings indicate that expression levels of NPM affected its localization. Our study also revealed a novel granular staining pattern for NPM, which was an independent prognostic factor of poor prognosis. In addition, reduced levels of NPM protein were associated with poor prognosis. Furthermore, luminal epithelial cells of histologically normal breast displayed high levels of NPM and overexpression of NPM in the invasive MDA-MB-231 cells abrogated their growth in soft agar. These results support a tumor suppressive role for NPM in breast cancer.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689627      PMCID: PMC3157231          DOI: 10.1016/j.ajpath.2011.04.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome.

Authors:  Luigi Cicatiello; Claudio Scafoglio; Lucia Altucci; Massimo Cancemi; Guido Natoli; Angelo Facchiano; Giovanni Iazzetti; Raffaele Calogero; Nicoletta Biglia; Michele De Bortoli; Christian Sfiligoi; Piero Sismondi; Francesco Bresciani; Alessandro Weisz
Journal:  J Mol Endocrinol       Date:  2004-06       Impact factor: 5.098

2.  Alterations in immunolocalization of the phosphoprotein B23 in HeLa cells during serum starvation.

Authors:  P K Chan; M Aldrich; H Busch
Journal:  Exp Cell Res       Date:  1985-11       Impact factor: 3.905

3.  Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals.

Authors:  N Feuerstein; P K Chan; J J Mond
Journal:  J Biol Chem       Date:  1988-08-05       Impact factor: 5.157

4.  Casein kinase II accumulation in the nucleolus and its role in nucleolar phosphorylation.

Authors:  M Pfaff; F A Anderer
Journal:  Biochim Biophys Acta       Date:  1988-04-02

5.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 6.  Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response.

Authors:  Sari Kurki; Karita Peltonen; Marikki Laiho
Journal:  Cell Cycle       Date:  2004-08-08       Impact factor: 4.534

7.  Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation.

Authors:  Sari Kurki; Karita Peltonen; Leena Latonen; Taija M Kiviharju; Päivi M Ojala; David Meek; Marikki Laiho
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

8.  KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

Authors:  Ronald Simon; Soti Panussis; Robert Maurer; Hanspeter Spichtin; Kathrin Glatz; Coya Tapia; Martina Mirlacher; Alex Rufle; Joachim Torhorst; Guido Sauter
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

9.  Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23.

Authors:  David Bertwistle; Masataka Sugimoto; Charles J Sherr
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

10.  Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase.

Authors:  Ko Sato; Ryosuke Hayami; Wenwen Wu; Toru Nishikawa; Hiroyuki Nishikawa; Yoshiko Okuda; Haruki Ogata; Mamoru Fukuda; Tomohiko Ohta
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

View more
  15 in total

Review 1.  Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Authors:  Joel G Turner; Jana Dawson; Christopher L Cubitt; Rachid Baz; Daniel M Sullivan
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

Review 2.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

3.  Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.

Authors:  Jun Li; Hongyan Li; Igor Makunin; Bryony A Thompson; Kayoko Tao; Erin L Young; Jacqueline Lopez; Nicola J Camp; Sean V Tavtigian; Esther M John; Irene L Andrulis; Kum Kum Khanna; David Goldgar; Georgia Chenevix-Trench
Journal:  Breast Cancer Res Treat       Date:  2017-08-24       Impact factor: 4.872

4.  Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications.

Authors:  Mariana Ferreira Leal; Tatiane Katsue Furuya Mazzotti; Danielle Queiroz Calcagno; Priscila Daniele Ramos Cirilo; Margarita Cortes Martinez; Samia Demachki; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília Cardoso Smith
Journal:  BMC Gastroenterol       Date:  2014-01-10       Impact factor: 3.067

5.  Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-α signaling.

Authors:  Yunxiao Zhou; Jie Shen; Liqun Xia; Yanli Wang
Journal:  Cancer Cell Int       Date:  2014-12-20       Impact factor: 5.722

6.  Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma.

Authors:  Mei Liu; Armando Varela-Ramirez; Jitian Li; Liping Dai; Renato J Aguilera; Jian-Ying Zhang
Journal:  Oncol Rep       Date:  2015-03-16       Impact factor: 3.906

Review 7.  Nucleophosmin: from structure and function to disease development.

Authors:  Joseph K Box; Nicolas Paquet; Mark N Adams; Didier Boucher; Emma Bolderson; Kenneth J O'Byrne; Derek J Richard
Journal:  BMC Mol Biol       Date:  2016-08-24       Impact factor: 2.946

8.  Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin.

Authors:  L Lam; Z Aktary; M Bishay; C Werkman; C-Y Kuo; M Heacock; N Srivastava; J R Mackey; M Pasdar
Journal:  Oncogenesis       Date:  2012-03-19       Impact factor: 7.485

9.  Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients.

Authors:  Antonia Patsialou; Yarong Wang; Juan Lin; Kathleen Whitney; Sumanta Goswami; Paraic A Kenny; John S Condeelis
Journal:  Breast Cancer Res       Date:  2012-10-31       Impact factor: 6.466

10.  NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.

Authors:  Karl Holmberg Olausson; Tamador Elsir; Kaveh Moazemi Goudarzi; Monica Nistér; Mikael S Lindström
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.